RC48 Treatment for Platinum Sensitive Recurrent Ovarian Cancer With HER2 Expression
Status:
RECRUITING
Trial end date:
2027-09-17
Target enrollment:
Participant gender:
Summary
The purpose of this study is to evaluate the efficacy, safety, and quality of life scores of patients with HER2-expressing platinum-sensitive recurrent epithelial ovarian cancer treated with the combination therapy regimen of RC48 plus platinum with or without bevacizumab.